<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(58)</volume><submitter>Sinan Tokalı F</submitter><pubmed_abstract>Alzheimer's disease (AD) is a neurodegenerative disorder with a gradual increase in severity. The underlying cause of the disease is the dysfunction of cholinergic neurotransmission affecting mainly the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Within the context of the present research, a new group of 3,5-disubstituted rhodanine derivatives containing tertiary amine groups has been prepared and their potency in the inhibition of AChE and BChE was assessed. Enzymatic assays demonstrated that compounds 6 and 11 exhibited exceptional inhibitory potency, with &lt;i>K&lt;/i> &lt;sub>i&lt;/sub> values of 13.61 nM and 12.70 nM against AChE, and 10.44 nM and 25.11 nM against BChE, respectively, surpassing the reference inhibitors tacrine (145.21 nM for AChE and 169.54 nM for B</pubmed_abstract><journal>RSC advances</journal><pagination>50186-50205</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12704249</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>New Mannich-type arylidenerhodanines as potent inhibitors of AChE and BChE: synthesis, biological evaluation, cytotoxicity and molecular modeling.</pubmed_title><pmcid>PMC12704249</pmcid><pubmed_authors>Ulucay O</pubmed_authors><pubmed_authors>Senol H</pubmed_authors><pubmed_authors>Shafiq Z</pubmed_authors><pubmed_authors>Ameen M</pubmed_authors><pubmed_authors>Demir Y</pubmed_authors><pubmed_authors>Sinan Tokalı F</pubmed_authors></additional><is_claimable>false</is_claimable><name>New Mannich-type arylidenerhodanines as potent inhibitors of AChE and BChE: synthesis, biological evaluation, cytotoxicity and molecular modeling.</name><description>Alzheimer's disease (AD) is a neurodegenerative disorder with a gradual increase in severity. The underlying cause of the disease is the dysfunction of cholinergic neurotransmission affecting mainly the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Within the context of the present research, a new group of 3,5-disubstituted rhodanine derivatives containing tertiary amine groups has been prepared and their potency in the inhibition of AChE and BChE was assessed. Enzymatic assays demonstrated that compounds 6 and 11 exhibited exceptional inhibitory potency, with &lt;i>K&lt;/i> &lt;sub>i&lt;/sub> values of 13.61 nM and 12.70 nM against AChE, and 10.44 nM and 25.11 nM against BChE, respectively, surpassing the reference inhibitors tacrine (145.21 nM for AChE and 169.54 nM for B</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T04:20:21.701Z</modification><creation>2026-05-25T03:12:06.874Z</creation></dates><accession>S-EPMC12704249</accession><cross_references><pubmed>41403678</pubmed><doi>10.1039/d5ra07416a</doi></cross_references></HashMap>